Tags

Type your tag names separated by a space and hit enter

Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine.
J Assoc Physicians India. 2003 Jul; 51:655-8.JA

Abstract

OBJECTIVES

1. To compare the protective antibody titres on day 14, 30 and 90 after giving intramuscular (IM) injections of PCECV and subcutaneous injections of Nervous Tissue Vaccine. 2. To compare the immunogenicity and safety of PCECV and NTV.

METHODS AND MATERIALS

The study enrolled cases in three groups. Group 'C' or control group: (n = 38) : This group comprised of 38 normal healthy volunteers without dog-bite. Group 'A' (n = 102): This group included cases of dog-bite fulfilling inclusion/exclusion criteria. Each one of Group A and C were given PCECV as post exposure treatment (PET) on day 0-3-7-14-30 and 90. Group 'B' (n = 50): This group included 50 cases of dog-bite who received NTV. The rabies virus neutralizing antibody titres were estimated by RFFIT (Rapid Fluorescent Focus Inhibition Test) on day 0, 14, 30 and 90 days. 45 recipients of PCECV were re-tested for persistence of Protective Antibodies at the end of 1 year.

RESULTS

Of these 37, 91 and 45 cases were evaluable in Groups C, A and B respectively. The antibody titres in Groups A, B, C were 13.4, 3.2, 22.8 IU/ml respectively; the protective titre being 0.5 IU/ml.5% PCECV recepients had delayed response on day 30.14% of NTV recepients did not seroconvert.

CONCLUSIONS

The Immunogenicity, Reactogenicity and safety of PCECV is well established. 5% of PCECV receipients showed a delayed sero conversion. 14% of NTV receipients did not sero convert at all. Therefore it is desirable to estimate antibody titres on day 14 after vaccination. If difficult, then all the cases of animal bite must receive passive immunization with rabies immunoglobulins.

Authors+Show Affiliations

Department of Medicine, Grant Medical College, Mumbai.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14621031

Citation

Deshpande, Alaka K., et al. "Comparative Evaluation of Immunogenicity, Reactogenecity and Safety of Purified Chick Embryo Cell Rabies Vaccine and Neural Tissue Rabies Vaccine." The Journal of the Association of Physicians of India, vol. 51, 2003, pp. 655-8.
Deshpande AK, Londhe VA, Akarte S, et al. Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. J Assoc Physicians India. 2003;51:655-8.
Deshpande, A. K., Londhe, V. A., Akarte, S., & Briggs, D. (2003). Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. The Journal of the Association of Physicians of India, 51, 655-8.
Deshpande AK, et al. Comparative Evaluation of Immunogenicity, Reactogenecity and Safety of Purified Chick Embryo Cell Rabies Vaccine and Neural Tissue Rabies Vaccine. J Assoc Physicians India. 2003;51:655-8. PubMed PMID: 14621031.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. AU - Deshpande,Alaka K, AU - Londhe,V A, AU - Akarte,Sulabha, AU - Briggs,Deborrah, PY - 2003/11/19/pubmed PY - 2004/6/15/medline PY - 2003/11/19/entrez SP - 655 EP - 8 JF - The Journal of the Association of Physicians of India JO - J Assoc Physicians India VL - 51 N2 - OBJECTIVES: 1. To compare the protective antibody titres on day 14, 30 and 90 after giving intramuscular (IM) injections of PCECV and subcutaneous injections of Nervous Tissue Vaccine. 2. To compare the immunogenicity and safety of PCECV and NTV. METHODS AND MATERIALS: The study enrolled cases in three groups. Group 'C' or control group: (n = 38) : This group comprised of 38 normal healthy volunteers without dog-bite. Group 'A' (n = 102): This group included cases of dog-bite fulfilling inclusion/exclusion criteria. Each one of Group A and C were given PCECV as post exposure treatment (PET) on day 0-3-7-14-30 and 90. Group 'B' (n = 50): This group included 50 cases of dog-bite who received NTV. The rabies virus neutralizing antibody titres were estimated by RFFIT (Rapid Fluorescent Focus Inhibition Test) on day 0, 14, 30 and 90 days. 45 recipients of PCECV were re-tested for persistence of Protective Antibodies at the end of 1 year. RESULTS: Of these 37, 91 and 45 cases were evaluable in Groups C, A and B respectively. The antibody titres in Groups A, B, C were 13.4, 3.2, 22.8 IU/ml respectively; the protective titre being 0.5 IU/ml.5% PCECV recepients had delayed response on day 30.14% of NTV recepients did not seroconvert. CONCLUSIONS: The Immunogenicity, Reactogenicity and safety of PCECV is well established. 5% of PCECV receipients showed a delayed sero conversion. 14% of NTV receipients did not sero convert at all. Therefore it is desirable to estimate antibody titres on day 14 after vaccination. If difficult, then all the cases of animal bite must receive passive immunization with rabies immunoglobulins. SN - 0004-5772 UR - https://www.unboundmedicine.com/medline/citation/14621031/Comparative_evaluation_of_immunogenicity_reactogenecity_and_safety_of_purified_chick_embryo_cell_rabies_vaccine_and_neural_tissue_rabies_vaccine_ L2 - http://www.diseaseinfosearch.org/result/6131 DB - PRIME DP - Unbound Medicine ER -